Log in Demo Start free trial

S-1 primary document

AKTX · Registration Statement (Form S-1) · Filed May 8, 2026

Akari Therapeutics PLC — S-1 exhibit

ex107.htm

Akari Therapeutics PLC on Boardroom Alpha

EX-FILING FEES

Calculation of Filing Fee Tables
S-1
Akari Therapeutics Plc

Table 1: Newly Registered and Carry Forward Securities	☐Not Applicable

		Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial Effective Date	Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to be Paid	1	Equity	Ordinary shares, nominal value $0.000000005 per share ("ordinary shares"), as represented by American Depositary Shares ("ADSs")	457(o)			$ 7,500,000.00	0.0001381	$ 1,035.75
Fees to be Paid	2	Other	Pre-funded warrants to purchase ordinary shares, as represented by ADSs	Other			$ 0.00	0.0001381	$ 0.00
Fees to be Paid	3	Equity	Ordinary shares, as represented by ADSs, issuable upon exercise of the pre-funded warrants	457(o)			$ 0.00	0.0001381	$ 0.00
Fees to be Paid	4	Other	Series H common warrants to purchase ordinary shares, as represented by ADSs	Other			$ 0.00	0.0001381	$ 0.00
Fees to be Paid		Equity	Ordinary shares, as represented by ADSs, issuable upon exercise of the Series H common warrants	457(o)			$ 7,500,000.00	0.0001381	$ 1,035.75
Fees to be Paid	5	Other	Series I common warrants to purchase ordinary shares, as represented by ADSs	Other			$ 0.00	0.0001381	$ 0.00
Fees to be Paid		Equity	Ordinary shares, as represented by ADSs, issuable upon exercise of the Series I common warrants	457(o)			$ 7,500,000.00	0.0001381	$ 1,035.75
Fees to be Paid	6	Other	Placement agent warrants to purchase ordinary shares, as represented by ADSs	Other			$ 0.00	0.0001381	$ 0.00
Fees to be Paid	7	Equity	Ordinary shares, as represented by ADSs, issuable upon exercise of the placement agent warrants	457(o)			$ 281,250.00	0.0001381	$ 38.84
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities
			Total Offering Amounts:				$ 22,781,250.00		$ 3,146.09
			Total Fees Previously Paid:						$ 0.00
			Total Fee Offsets:						$ 0.00
			Net Fee Due:						$ 3,146.09

Offering Note

¹	Security Class Title - Amount Registered: Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the ordinary shares as represented by ADSs registered hereby also include an indeterminate number of additional ordinary shares as represented by ADSs as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions. Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act.

²	The registrant may issue pre-funded warrants to purchase ordinary shares as represented by ADSs in the offering. The purchase price of each pre-funded warrant will equal the price per share at which the ADSs are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.001 per ADS (subject to adjustment as provided for therein). The proposed maximum aggregate offering price of the ordinary shares as represented by ADSs will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ordinary shares as represented by ADSs issued in the offering. Accordingly, the proposed maximum aggregate offering price of the ordinary shares as represented by ADSs and pre-funded warrants (including the ordinary shares as represented by ADSs issuable upon exercise of the pre-funded warrants), if any, is $7,500,000. No separate fee is required pursuant to Rule 457(g) of the Securities Act.

³	The registrant may issue pre-funded warrants to purchase ordinary shares as represented by ADSs in the offering. The purchase price of each pre-funded warrant will equal the price per share at which the ADSs are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.001 per ADS (subject to adjustment as provided for therein). The proposed maximum aggregate offering price of the ordinary shares as represented by ADSs will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ordinary shares issued in the offering. Accordingly, the proposed maximum aggregate offering price of the ordinary shares as represented by ADSs and pre-funded warrants (including the ordinary shares as represented by ADSs issuable upon exercise of the pre-funded warrants), if any, is $7,500,000.

⁴	No separate fee is required pursuant to Rule 457(g) of the Securities Act.

⁵	No separate fee is required pursuant to Rule 457(g) of the Securities Act.

⁶	No separate fee is required pursuant to Rule 457(g) of the Securities Act.

⁷	As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act, the proposed maximum aggregate offering price of the placement agent's warrants is $281,250, which is equal to 3.0% of the aggregate value of the ADSs to be sold in the offering at an exercise price equal to 125% of the public offering price per share.

Table 2: Fee Offset Claims and Sources	☑Not Applicable

		Registrant or Filer Name	Form or Filing Type	File Number	Initial Filing Date	Filing Date	Fee Offset Claimed	Security Type Associated with Fee Offset Claimed	Security Title Associated with Fee Offset Claimed	Unsold Securities Associated with Fee Offset Claimed	Unsold Aggregate Offering Amount Associated with Fee Offset Claimed	Fee Paid with Fee Offset Source
Rules 457(b) and 0-11(a)(2)
Fee Offset Claims
Fee Offset Sources
Rule 457(p)
Fee Offset Claims
Fee Offset Sources

Table 3: Combined Prospectuses	☑Not Applicable

	Security Type	Security Class Title	Amount of Securities Previously Registered	Maximum Aggregate Offering Price of Securities Previously Registered	Form Type	File Number	Initial Effective Date

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer